Form 4: First Wave BioPharma CFO Sells Shares to Cover Tax Obligations

Sarah Romano, CFO of First Wave BioPharma, Inc., sold 1,120 shares of common stock on March 15, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• On March 15, 2024, Sarah Romano, the Chief Financial Officer of First Wave BioPharma, Inc., sold 1,120 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $4.96, with individual transactions ranging from $4.90 to $5.175.
• Following the transaction, Romano directly owns 19,186 shares, which includes unvested RSUs.

Sentiment

Score: 5

Explanation: The document reflects a neutral event (stock sale for tax obligations) with no inherent positive or negative implications for the company's overall prospects.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company officers and directors. This transaction appears to be a standard 'sell to cover' arrangement, common for executives receiving equity compensation.

Stakeholder Impact

• The sale of shares by an officer could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Form 4, First Wave BioPharma, FWBI, Sarah Romano, CFO, Stock Sale, Restricted Stock Units, RSUs, Tax Withholding